India’s Capital First, a fast-growing provider of loans to consumers and small businesses backed by buyout firm Warburg Pincus, said on Saturday, January 13, it would sell itself in a US$1.5 billion all-share deal to infrastructure lender IDFC Bank.
The buyer upgrades its retail business and brings a highly rated executive on board. The seller gets the bank license it always wanted.
Capital First’s market value has grown ten-fold in the five years since it rebranded. Chairman V. Vaidyanathan, who earlier built the successful retail business at ICICI Bank, has grown a US$3.5 billion loan book extending small sums to entrepreneurs and the emerging middle class. Net profit has grown at an impressive 40% compound annual rate for five years, and net non-performing loans are around just 1% of the overall book.
IDFC Bank earns half the return on equity of Capital First, and so trades at half the valuation, at a price of 1.4 times forward book value. The buyer scrapped a fiddly merger last year with part of Ajay Piramal-backed Shriram Group, which would have accelerated the growth of its retail business.
Full Content: The Economic Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan